Literature DB >> 3968684

Analogues of aminoglutethimide: selective inhibition of aromatase.

A B Foster, M Jarman, C S Leung, M G Rowlands, G N Taylor, R G Plevey, P Sampson.   

Abstract

In exploring further the structural features that influence the relative efficacy of analogues of aminoglutethimide [1, 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione] as inhibitors of the cholesterol side-chain cleavage enzyme system desmolase and the estrogen forming system aromatase, analogues have been synthesized in which the aminophenyl substituent is replaced by pyridyl or substituted pyridyl. The 4-pyridyl analogue 5 [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione] is a strong competitive inhibitor of aromatase (Ki = 1.1 microM; value for 1, 0.60 microM), which exhibits a type II difference spectrum (Ks = 0.28 microM; value for 1, 0.13 microM) but is noninhibitory toward desmolase. The 2- and 3-pyridyl analogues (3 and 4) inhibit neither enzyme system. 1-Amino-3-ethyl-3-phenylpiperidine-2,6-dione (2) is a strong and selective inhibitor of desmolase but the 4-pyridyl analogue 10 [1-amino-3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione] is a weak inhibitor of desmolase and aromatase. Analogues of 5 having a less basic aromatic substituent, namely, the N-oxide 11 and the 2,3,5,6-tetrafluoro derivative 13, were also prepared. The latter is a weak inhibitor of aromatase and the former inhibits neither enzyme system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968684     DOI: 10.1021/jm00380a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.

Authors:  G K Poon; G M Bisset; P Mistry
Journal:  J Am Soc Mass Spectrom       Date:  1993-07       Impact factor: 3.109

3.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 4.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

5.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain.

Authors:  Rebecca Stadel; Jun Yang; Julia W Nalwalk; James G Phillips; Lindsay B Hough
Journal:  Drug Metab Dispos       Date:  2007-12-19       Impact factor: 3.922

Review 7.  Aromatase inhibitors--mechanisms for non-steroidal inhibitors.

Authors:  H V Vanden Bossche; H Moereels; L M Koymans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  Treatment of breast cancer with aromatase inhibitors--current status and future prospects.

Authors:  P E Lønning; M Dowsett; T J Powles
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

9.  The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.

Authors:  F A MacNeill; A L Jones; S Jacobs; P E Lønning; T J Powles; M Dowsett
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

10.  Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

Authors:  M Dowsett; F MacNeill; A Mehta; C Newton; B Haynes; A Jones; M Jarman; P Lonning; T J Powles; R C Coombes
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.